Toward predictive signatures of enzalutamide response and resistance

European Urology

Volumn 67, Issue 1, 2015, Pages 61-63

  Gleave, Martin ^a   Chi, Kim ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CHLOROPLAST DNA; ENZALUTAMIDE; FLUTAMIDE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ANDROGEN SYNTHESIS; BONE BIOPSY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; DNA SEQUENCE; DRUG RESISTANCE; DRUG RESPONSE; EDITORIAL; GENE DOSAGE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRESS; ANALOGS AND DERIVATIVES; BONE MARROW NEOPLASMS; BONE NEOPLASMS; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTINEOPLASTIC AGENTS; BONE MARROW NEOPLASMS; BONE NEOPLASMS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84926220891     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.012     Document Type: Editorial

References (13)

1. E. Efstathiou, M. Titus, and S. Wen Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer Eur Urol 67 2015 53 60
2. E. Efstathiou, M. Titus, and D. Tsavachidou Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone J Clin Oncol 30 2012 637 643
3. Montgomery B, Kheoh T, Molina A, et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.06.042
4. J.A. Locke, E.S. Guns, and A.A. Lubik Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
5. M. Korpal, J.M. Korn, and X. Gao An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov 3 2013 1030 1043
6. S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, and D.J. Tindall Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 2008 5469 5477
7. Z. Guo, X. Yang, and F. Sun A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
8. S. Sun, C.C. Sprenger, and R.L. Vessella Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
9. B.S. Carver, C. Chapinski, and J. Wongvipat Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
10. H. Matsumoto, Y. Yamamoto, and M. Shiota Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability Cancer Res 73 2013 5206 5217
11. A. Zoubeidi, A. Zardan, and R.M. Wiedmann Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD Cancer Res 70 2010 2307 2317
12. A. Azad, S. Volik, A. Wyatt, A. Haegert, C. Collins, and K.N. Chi Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) and enzalutamide (enza) [abstract 5021] J Clin Oncol 32 Suppl 2014
13. E.S. Antonarakis, C. Lu, and H. Wang Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) [abstract 5001] J Clin Oncol 32 Suppl 2014